OPT - Opthea to Present at the OIS Retina Innovation Summit at ARVO | Benzinga
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company's clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.
OIS Retina Innovation Summit Details